Skip to content

Source filing unavailable

Q1 2024 · —
Revenue—
Net Income-$8.30MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$5.40no prior Q1 2023 on fileno prior Q4 2023 on file
Operating Income-$7,773,254—
Operating Cash Flow-$5,247,582—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2024Q1 2023
Net Income-$8.30M-$5.27M
EPS Diluted-$5.40—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR